Background: CA 125 assays enable treatment-response monitoring in ovarian cancer. Patients and methods: A multicentric study of CA 125 kinetics under induction chemotherapy was performed in 631 patients. CA 125 half-life was calculated by mono-compartmental logarithmic regression. Nadir CA 125 concentration and time to nadir were also studied. Survival analyses for disease-free survival (DFS) and overall survival (OS) used univariate (Kaplan-Meier) and multivariate (Cox) models.
introduction
In oncology, treatment responses need to be classified according to standard definitions, such as the widely accepted RECIST (Response Evaluation Criteria in Solid Tumours) guideline [1] . However, in ovarian cancer patients without measurable targets, responses cannot be assessed using the RECIST criteria. The CA 125 tumour marker, elevated in 90% of patients with advanced epithelial ovarian cancer, represents an alternative to monitoring treatment responses.
Different prognostic and predictive criteria derived from CA 125 variations under induction chemotherapy have been investigated. Most of the previous studies of CA 125 under chemotherapy included less than 100 patients and there is still no agreement about the prognostic value of post-operative CA 125 [2] [3] [4] [5] [6] [7] . A first approach consisted in defining responses according to precise criteria for CA 125 decrease [8] [9] [10] [11] [12] [13] . Study of CA 125 half-life [2, 5, 7, [14] [15] [16] [17] [18] [19] [20] [21] , CA 125 return to normal range after 2 or 3 chemotherapy courses [5-7, 18-19, 22] , nadir CA 125 concentrations [4, 23] and time to reach the nadir [9] were also investigated. We performed a multicentric study with a large cohort of ovarian cancer patients during and after primary treatment to analyse the long term prognostic value of the different criteria linked to CA 125 kinetics. [25] . The number and location of extra-abdominal metastatic sites were recorded. Histological type was determined according to World Health Organisation classification and was grouped into serous, mucinous, endometroid, undifferentiated, clear cell and of unknown histology [26] . Tumour grading was not included in the analyses because of insufficient reproducibility [24] . Residual tumour after primary surgery was classified into three groups: absence, £ 1 cm or > 1 cm.
patients and methods
Induction chemotherapy started 2 to 4 weeks after surgery and patients received 6 ± 1.9 (mean ± SD) chemotherapy courses. Treatment evaluation was based on biological and clinical data recorded at each cycle and on medical imaging. During and after chemotherapy, chest X-rays, abdomino-pelvic scans, MRI or ultrasonography were performed according to identified targets.
Serum CA 125 was measured prior to each cycle (on average each 3 weeks) using the same immunoassay during monitoring.
CA 125 assays
Assays were performed following manufacturer recommendations. All Centres used immunoassays based on monoclonal Centocor/FujirebioÒ antibodies but with different assay formats: IRMA-mat CA 125 II (immunoradiometric assay, DiaSorin, Antony, France) was used for 105 patients from Bordeaux Centre, CPE CA 125 II (enzyme-immunoassay, Cis Bio International, Gif sur Yvette, France) was used in Dijon and Toulouse Centres for 199 patients, and ELSA CA 125 II (immunoradiometric assay, Cis Bio International, Gif sur Yvette, France) was used for 327 patients monitored in Angers, Nantes, Reims, Saint-Cloud and Rouen Centres.
All assays were run in duplicate with two levels of control sera in each series. Samples showing more than 10% variation between duplicates were re-assayed. The threshold for CA 125 elevation indicated by the manufacturers was 35 kU/l for all methods.
CA 125 kinetics
Serum CA 125 was measured 1-4 days before the first chemotherapy cycle. Mean interval between the date of surgery and the first chemotherapy course was 20 ± 7 days. The lowest CA 125 concentration reached during or after chemotherapy (nadir) and the time elapsed from start of chemotherapy to nadir were also recorded. CA 125 half-life (T1/2) calculation, considered as an early indicator of tumour chemo-sensitivity, was based on a mono-compartmental model and an exponential regression: T1/2 = Ln 2/s, where s is the slope of the regression line and Ln the natural logarithm. A minimum of three serial and aligned Ln CA 125 concentrations in the first six blood samples was required to enable regression line calculation. The regression was considered significant only if its correlation coefficient r was ‡ 0.95, allowing CA 125 half-life results to be taken into account. To ensure unbiased calculations of CA 125 half-life, only cases with pre-chemotherapy CA 125 ‡ 100 kU/l were included in statistical analyses.
statistical methods
Disease-free survival (DFS) was defined as the time elapsed from the date of the first chemotherapy cycle to the date of clinically proven recurrence. Overall survival (OS) was calculated from the date of the first chemotherapy cycle to the date of cancer-related death. Patients without recurrences or still alive were censored at study endpoint (May 30, 2005) .
Since the post-operative CA 125 distribution was not Gaussian, non-parametric statistics were used. The Chi-square test was used for comparison of observed frequencies. Receiver operating characteristics curves (ROC) were used to define the thresholds of CA 125 kinetics parameters in view of survival analyses.
Univariate survival analyses were performed using the Kaplan-Meier method and log-rank test [27] . Cox models were used for multivariate survival analyses [28] . For all statistical tests, the level of significance was P £ 0.05. Statistical softwares used were SAS v. 8.2 (Cary, NC, USA) and MedCalc v. 8.0 (Mariakerke, Belgium). results patients Six hundred and thirty one patients were included in this multicentric study. Thirty-three patients (5%) were removed because of incomplete serial CA 125 measures, absence of chemotherapy, treatment including taxanes, or deaths unrelated to ovarian cancer. For prognostic studies, only stage IIC to IV patients were included (n = 553). Their main characteristics are summarised in Table 1 . Ascites was noted for 393 (62.3%) patients. Eighty-four percent of the patients received chemotherapy including cyclophosphamide + platinum salts, 16 % cyclophosphamide + platinum salts + anthracycline with a mean ± SD number of cycles of 6.1 ± 1.9 and 5.4 ± 2.3 respectively. 214 months) and median OS was 32 months (range 2-214 months). The four parameters linked to CA 125 kinetics had a strong prognostic value for DFS and OS with P < 0.0001 (Table 2) .
multivariate survival models
For the variable CA 125 half-time, only cases with validated half-life calculation (i.e. pre-chemotherpy CA 125 ‡ 100 kU/l) were included (n = 415). During follow up, 459 recurrences and 444 deaths were recorded in the IIC-IV group, including 364 recurrences and 356 deaths in the subgroup with validated half-life calculation. Clinico-pathological variables introduced in the Cox models were: age, (continuous or dichotomised with 50 years as cut-off), FIGO stage, residual tumour mass and tumour histology in three groups (serous, mucinous or undifferenciated). Parameters related to CA 125 kinetics were introduced as continuous and as dichotomised variables. For the whole population (n = 553), the models obtained were identical for DFS and OS, with CA 125 nadir and residual tumour ranking first (all with P < 0.0001) followed by age as a continuous variable (P = 0.0236 for DFS and P = 0.0019 for OS) and FIGO stage (P = 0.0236 for DFS and P = 0.0072 for OS). Table 3 shows the results of Cox models for DFS and OS in the subgroup with validated CA 125 half-life. It is now widely accepted that the tumour marker CA 125 is a predictive and prognostic factor in CA 125 positive ovarian cancers. Different criteria derived from CA 125 kinetics during primary treatment have been investigated [2, 5, 11, 17, 19] . When calculating CA 125 half-life most of the authors, except Buller, used only two selected time points, i.e. before chemotherapy and up to 3 months later. This implies that the CA 125 decrease under chemotherapy always follows a mono-compartmental model. Our results provide the basis for this assumption. Rustin proposed another set of criteria based on assigned proportions of CA 125 decrease with two or three serial samples [10] . All objective criteria derived from CA 125 kinetics under induction chemotherapy were compared in a large series of patients with a long follow up time. Our results show that, among other well-established prognostic factors in ovarian cancers, two parameters bear a strong and independent prognostic value: CA 125 half-life and CA 125 nadir concentration. To be reliable, the CA 125 half-life should be calculated from the start of chemotherapy on a minimum 
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of three serial samples enabling the calculation of a regression line and a correlation coefficient. This method is now widely accessible through software provided with immunoassay equipment or by using popular spreadsheets. Its only drawback is when the pre-chemotherapy CA 125 is too low (< 100 kU/l) to enable half-life calculations. However, most of the ovarian cancers are detected in advanced stages, 70% in stages III and IV, and show elevated CA 125 levels after primary surgery [6] . Furthermore, the CA 125 nadir, the second powerful criteria from our results, is available even if CA 125 half-life cannot be ascertained. It is noteworthy that the discriminant cut-off found for CA 125 nadir (20 kU/l) for DFS and OS in stage IIC-IV patients is significantly lower than the usual cut-off proposed by manufacturers (35 kU/l). The latter was established for untreated ovarian cancer patients without taking into account patient menopausal status. To conclude, CA 125 half life and nadir concentration are powerful independent prognostic factors which warrants to be compared to the classical prognostic factors in prospective protocols of ovarian cancers treatment.
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